Illustration of substances being released at a cell’s surface leading to inflammation
Illustration of substances being released at a cell’s surface leading to inflammation
Immunology
We delivered the first advanced biologic for atopic dermatitis with Regeneron. Now we’re following the science to get inflammation under control and restore immune balance in many other diseases.
Did You Know
2
5
Type 2 inflammation can go into overdrive. Our flagship medicine with Regeneron is approved to treat five different diseases caused in part by this.
13
A Pioneer in Type 2 Inflammation
In less than a decade, with Regeneron, we changed the lives of many people with atopic dermatitis. Then we asked, "Can we take this science further?"
We did. We helped people living in fear of their next asthma attack, and those suffering from chronic rhinosinusitis with nasal polyposis. We’re still going, unlocking potential treatments for people with dermatologic, respiratory, and gastrointestinal diseases.
Restoring Immune Balance
We’re exploring immune disorders beyond type 2 inflammation using our precision immunology approach.
Our teams are helping rebalance the immune system using new technologies to tackle diseases like adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile arthritis.
Inspired by Patients
Taking Down Type 2 Inflammation
What do atopic dermatitis, asthma, and many other conditions have in common?
The Next Breath
Improving Quality of Care in Atopic Dermatitis
What we learned from the 2020 report
What’s Next in Immunology?
Where will we go next? We'll push the science of immunology further and continue learning from our friends and neighbors who know their diseases better than anyone.
They’re counting on us. That’s why we will never settle.
Do You Want to Participate in a Clinical Trial at Sanofi?
Our Latest Stories
September 29, 2025
A Mother’s Story and Our Journey Living with ITP
References
- Gieseck RL 3rd, Wilson MS, Wynn TA (2018) Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol 18:62-76; DOI: 10.1038/nri.2017.90